Dianthus Therapeutics, Inc. /DE/ Deferred Revenue (Non-Current)
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Deferred Revenue (Non-Current) of $5.94 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2026-08-04
- 2026-06-30: Deferred Revenue, Noncurrent $5.94M.
- 2026-03-31: Deferred Revenue, Noncurrent $6.32M.
- 2025-12-31: Deferred Revenue, Noncurrent $5.77M.
- 2025-09-30: Deferred Revenue, Noncurrent $6.07M.
| Period end | Deferred Revenue, Noncurrent | Deferred Revenue, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $5.94M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $6.32M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $5.77M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $6.07M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.78M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.85M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $1.91M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $640.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $682.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $719.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 | $736.00K 10-K · filed 2024-03-21 |
| 2023-09-30 | $745.00K 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $791.00K 10-K · filed 2024-03-21 | |
| 2021-12-31 | $0.00 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |